Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.vbshilpa.com | |
Market Cap | 4,004.61 Cr. | |
Enterprise Value(EV) | 4,844.13 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -0.08 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 206.13 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 2.24 | Calculated using Price: 461.35 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 8.68 Cr. | 86,801,898 Shares |
FaceValue | 1 | |
About Shilpa Medicare Ltd. | ||
Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications. |
1 Day |
|
+1.45% |
1 Week |
|
+2.34% |
1 Month |
|
+6.86% |
3 Month |
|
+28.02% |
6 Month |
|
+30.20% |
1 Year |
|
+99.65% |
2 Year |
|
+15.12% |
5 Year |
|
+34.26% |
10 Year |
|
+136.48% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 15.4 | 17.66 | 12.85 | 9.93 | 9.59 | 12.23 | 10.41 | 3.67 | -1.71 | |
Return on Capital Employed (%) | 17.9 | 19.69 | 15.28 | 11.13 | 10.45 | 12.38 | 10.73 | 5.94 | 0.8 | |
Return on Assets (%) | 9.18 | 11.41 | 8.69 | 6.92 | 7.04 | 8.59 | 6.33 | 2.2 | -1.07 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 547 | 639 | 987 | 1,085 | 1,198 | 1,329 | 1,479 | 1,822 | 1,783 | 1,783 | |
Non Curr. Liab. | 154 | 67 | 251 | 153 | 167 | 257 | 561 | 453 | 345 | 599 | |
Curr. Liab. | 189 | 222 | 237 | 266 | 253 | 411 | 587 | 612 | 783 | 630 | |
Minority Int. | 14 | 2 | -3 | -5 | -8 | -8 | -11 | -11 | -9 | -9 | |
Equity & Liab. | 905 | 931 | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,876 | 2,902 | 3,004 | |
Non Curr. Assets | 577 | 577 | 742 | 827 | 1,065 | 1,365 | 1,730 | 1,988 | 2,134 | 2,179 | |
Curr. Assets | 328 | 354 | 730 | 672 | 545 | 624 | 862 | 887 | 768 | 825 | |
Misc. Exp. not W/O | 0 | ||||||||||
Total Assets | 905 | 931 | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,876 | 2,902 | 3,004 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 614 | 716 | 779 | 789 | 733 | 908 | 901 | 1,146 | 1,050 | 1,123 | |
Other Income | 7 | 11 | 29 | 33 | 16 | 22 | 40 | 21 | 31 | 8 | |
Total Income | 621 | 728 | 809 | 821 | 749 | 930 | 941 | 1,166 | 1,082 | 1,131 | |
Total Expenditure | -487 | -556 | -618 | -638 | -579 | -693 | -729 | -948 | -962 | -911 | |
PBIDT | 133 | 171 | 191 | 184 | 170 | 237 | 212 | 218 | 120 | 221 | |
Interest | -4 | -4 | -3 | -3 | -4 | -5 | -22 | -41 | -59 | -85 | |
Depreciation | -21 | -23 | -31 | -37 | -42 | -44 | -54 | -80 | -96 | -107 | |
Taxation | -35 | -36 | -42 | -34 | -26 | -33 | -49 | -42 | 7 | -23 | |
Exceptional Items | 0 | -2 | -5 | 20 | 61 | 9 | |||||
PAT | 73 | 105 | 104 | 103 | 110 | 155 | 146 | 61 | -31 | 5 | |
Minority Interest | 1 | 4 | 3 | 2 | 3 | 2 | 2 | 0 | -2 | 0 | |
Share Associate | -6 | ||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 74 | 108 | 108 | 105 | 112 | 156 | 148 | 61 | -32 | -1 | |
Adjusted EPS | 10 | 14 | 13 | 13 | 14 | 19 | 18 | 7 | -4 | 0 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 70 | 69 | 129 | 37 | 45 | 147 | 124 | 47 | 105 | 226 | |
Cash Fr. Inv. | -49 | -195 | -109 | -262 | -9 | -196 | -290 | -404 | -286 | -278 | |
Cash Fr. Finan. | -28 | 136 | -20 | 313 | -61 | 10 | 176 | 436 | 83 | 46 | |
Net Change | -7 | 10 | 0 | 88 | -25 | -39 | 10 | 79 | -98 | -7 | |
Cash & Cash Eqvt | 9 | 18 | 6 | 100 | 74 | 34 | 44 | 123 | 25 | 19 |
Thu, 28 Mar 2024
Closure of Trading Window Closure of Trading window notice |
Thu, 28 Mar 2024
Appointment Of Mr. Santosh Kumar Mahil As CEO Of Shilpa Pharma Lifesciences Limited A Wholly Owned Subsidiary Of Shilpa Medicare Limited Appointment of Mr. Santosh Kumar Mahil as CEO of Shilpa Pharma Lifesciences Limited a wholly owned subsidiary of Shilpa Medicare Limited |
Thu, 14 Mar 2024
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report Declaration of Postal Ballot results and Scrutinizers report with respect to Issue of Securities by way of QIP |
Thu, 28 Mar 2024 |
Close Crossing Last Month High |
Close Within 52 Week High Zone |
Close Above Last Month High |
High Increase in 1 Month |
High Increase in 3 Months |